Last reviewed · How we verify
ICARIIN
ICARIIN is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current market presence and patent protection. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | ICARIIN |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Topical Icariin on Acne and Acne Scars (NA)
- Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC (PHASE2)
- Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma (PHASE2)
- Icariin to Prevent Corticosteroid-related Memory Changes (PHASE1)
- Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |